By Fineline Cube 
Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United States and China, announced that it has received Investigational New Drug (IND) approval from the US FDA for its AVZO-1418/DB-1418. This potential best-in-class EGFR/HER3 bispecific antibody conjugate drug (ADC) represents a significant advancement in oncology treatment options.
AVZO-1418/DB-1418 Mechanism
AVZO-1418/DB-1418 is an EGFR/HER3 dual-targeting ADC based on topoisomerase-1 inhibitors. It was developed using DualityBio’s proprietary Duality Innovative Bispecific Antibody Conjugate (DIBAC) platform. Preclinical studies demonstrated higher binding affinity to tumor cells and efficacy across various solid tumors, including those resistant to EGFR or HER3.
Licensing Agreement
In January of this year, US-based oncology-focused biotech Avenzo Therapeutics, Inc. entered into a licensing agreement with Duality Biologics. Avenzo acquired exclusive global development, manufacturing, and commercialization rights to AVZO-1418/DB-1418, excluding Greater China.-Fineline Info & Tech